Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Zentalis Pharmaceuticals (Nasdaq: ZNTL) said management will participate in two investor events in November 2025: a Guggenheim Healthcare Innovation fireside on Nov 11, 2025 at 3:30 p.m. ET and a Stifel Healthcare presentation on Nov 12, 2025 at 8:00 a.m. ET.

Live webcasts and archived recordings will be available under the Events & Presentations tab on the company Investor & Media website. The company is a clinical-stage biopharma developing a WEE1 inhibitor for ovarian cancer and other tumors.

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis^® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the management team will participate in the following upcoming investor conferences:

• Guggenheim's 2nd Annual Healthcare Innovation Conference, Boston, MA.
  • Fireside discussion, November 11, 2025, 3:30 p.m. ET.
• Stifel 2025 Healthcare Conference, New York, NY.
  • Company presentation, November 12, 2025, 8:00 a.m. ET.

Access to live webcasts of the events, as well as an archived recording, will be available under the “Events & Presentations” tab on the Investors & Media section of the Company’s website. 

About Zentalis Pharmaceuticals
Zentalis^® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN- c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum- resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego. 

For more information, please visit www.zentalis.com. Follow Zentalis on LinkedIn at https://www.linkedin.com/company/zentalis-pharmaceuticals.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the potential for azenosertib to be first-in-class and best-in-class; the potential benefits of azenosertib, including the potential for azenosertib to be an important treatment option for patients with ovarian cancer or other tumor types; the broad franchise potential of azenosertib; and the potential to advance research on additional areas of opportunity for azenosertib outside PROC. The terms “advance,” “believe,” “develop,” “positions,” “potential,” and “will” and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; our substantial dependence on the success of azenosertib; our plans, including the costs thereof, of development of companion diagnostics; the outcome of preclinical testing and early trials may not be predictive of the success of later clinical trials; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process or ongoing regulatory obligations; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; effects of significant competition; the possibility of system failures or security breaches; risks relating to intellectual property; our ability to attract, retain and motivate qualified personnel, and risks relating to management transitions; significant costs as a result of operating as a public company; and the other important factors discussed under the caption “Risk Factors” in our most recently filed periodic report on Form 10-K or 10-Q and subsequent filings with the U.S. Securities and Exchange Commission (SEC) and our other filings with the SEC. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

ZENTALIS^® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.

Contact:
Aron Feingold
VP, Investor Relations & Corporate Communications
ir@zentalis.com

FAQ

When will Zentalis (ZNTL) present at Guggenheim's Healthcare Innovation Conference?

Zentalis management will appear in a fireside discussion on Nov 11, 2025 at 3:30 p.m. ET.

What time and date is Zentalis (ZNTL) presenting at the Stifel 2025 Healthcare Conference?

The company presentation is scheduled for Nov 12, 2025 at 8:00 a.m. ET.

Where can investors watch the Zentalis (ZNTL) webcasts for the November 2025 events?

Live webcasts and archived recordings are available under the Events & Presentations tab on the company Investor & Media website.

Will Zentalis (ZNTL) discuss clinical progress on its WEE1 inhibitor at the November 2025 conferences?

The announcement lists participation and presentation slots; attendees should check the webcasts for any clinical updates presented by management.

How can shareholders access the archived recording of Zentalis (ZNTL) presentations from Nov 2025?

Archived recordings will be posted under the Events & Presentations section of the company's Investor & Media website after each webcast.

Are the Nov 11–12, 2025 Zentalis (ZNTL) events open to the public or by invitation?

The company announced scheduled participation and will provide webcasts; specific event attendance rules are set by the conference organizers.